Your browser doesn't support javascript.
loading
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.
Durbin, Anna P; Kirkpatrick, Beth D; Pierce, Kristen K; Carmolli, Marya P; Tibery, Cecilia M; Grier, Palmtama L; Hynes, Noreen; Opert, Kari; Jarvis, Adrienne P; Sabundayo, Beulah P; McElvany, Benjamin D; Sendra, Eli A; Larsson, Catherine J; Jo, Matthew; Lovchik, Janece M; Luke, Catherine J; Walsh, Mary C; Fraser, Ellen A; Subbarao, Kanta; Whitehead, Stephen S.
Affiliation
  • Durbin AP; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Kirkpatrick BD; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Pierce KK; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Carmolli MP; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Tibery CM; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Grier PL; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Hynes N; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Opert K; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Jarvis AP; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Sabundayo BP; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • McElvany BD; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Sendra EA; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Larsson CJ; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Jo M; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Lovchik JM; Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore.
  • Luke CJ; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
  • Walsh MC; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Fraser EA; Vaccine Testing Center, University of Vermont College of Medicine, Burlington.
  • Subbarao K; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
  • Whitehead SS; Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland.
J Infect Dis ; 214(6): 832-5, 2016 Sep 15.
Article in En | MEDLINE | ID: mdl-26908742
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dengue / Dengue Vaccines / Antibodies, Neutralizing / Antibodies, Viral Type of study: Clinical_trials Limits: Adult / Humans Country/Region as subject: America do norte Language: En Journal: J Infect Dis Year: 2016 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dengue / Dengue Vaccines / Antibodies, Neutralizing / Antibodies, Viral Type of study: Clinical_trials Limits: Adult / Humans Country/Region as subject: America do norte Language: En Journal: J Infect Dis Year: 2016 Document type: Article Country of publication: United States